Cargando…

Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37

BACKGROUND: Chronic hepatitis C virus (HCV) infection leads to life-threatening complications worldwide. Immunomodulation signals the response to virus clearance. The immune-suppressive molecule human leukocyte antigen-G (HLA-G) has been shown to function in inhibiting both innate and adaptive immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Shi-xiong, Ma, Jian-bo, Hu, Yao-ren, Hu, Ai-rong, Shen, Qiang, Gao, Guo-sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915332/ https://www.ncbi.nlm.nih.gov/pubmed/27112970 http://dx.doi.org/10.12659/MSM.895971

Ejemplares similares

Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience
por: Kozielewicz, D., et al.
Publicado: (2011)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4
por: Domagalski, K., et al.
Publicado: (2013)

HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b
por: Fan, Zhijuan, et al.
Publicado: (2019)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy
por: Hu, Zhongjie, et al.
Publicado: (2015)

Plasma soluble human leukocyte antigen G predicts the long-term prognosis in patients with colorectal cancer
por: Jiao, Feiyan, et al.
Publicado: (2020)

Presence of HCV RNA in peripheral blood mononuclear cells may predict patients’ response to interferon and ribavirin therapy
por: Zaman, Nasib, et al.
Publicado: (2014)

IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection
por: Chen, J-Y, et al.
Publicado: (2011)

IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients
por: Aparicio, Ester, et al.
Publicado: (2010)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
por: Shaker, Olfat, et al.
Publicado: (2013)

U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients
por: Ho, Samuel B., et al.
Publicado: (2011)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation
por: Panigrahi, Rajesh, et al.
Publicado: (2013)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
por: Zhang, Geng-lin, et al.
Publicado: (2017)

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
por: Malaguarnera, Giulia, et al.
Publicado: (2016)

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
por: Kawaguchi, Takumi, et al.
Publicado: (2019)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC)
por: Gupta, Rahul, et al.
Publicado: (2012)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

IFN-α-2a (Interferon) and ribavirin induced suicidal attempt in a patient of chronic HCV: A rare case report
por: Inder, Deep, et al.
Publicado: (2011)

Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α
por: Keppeke, Gerson Dierley, et al.
Publicado: (2012)

Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection
por: Aizawa, Yoshio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_69sugk1r6jkbigcmj730gppdmn